Research Findings The clinical development program for retatrutide has produced some of the most impressive weight loss results ever documented in pharmacological obesity trials, generating significant excitement and positioning the compound as a potential paradigm-shifting therapy
Hernandez combines evidence-based metabolic medicine with pediatric endocrinology, nutrition, exercise physiology, behavioral health, and personalized lifestyle interventions to help children build healthier metabolism and lifelong wellness
Histologic resolution of non-alcoholic steatohepatitis has also been seen for liraglutide in subjects with or without T2D
Clinical trials with GLP-1 receptor agonists consistently demonstrate significant weight loss, with higher doses (such as semaglutide 2.4 mg weekly) producing approximately 15% average weight loss in adults without diabetes in clinical trials (somewhat less in type 2 diabetes) when combined with lifestyle modification
Patients who qualify may receive injection technique guidance, individualized dosing instructions, treatment education, and follow-up support
